Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric‐Bernstam, Shahneen Sandhu, Randy F. Sweis et al.|Clinical Cancer Research|2022Cited by 226
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, Gurkamal Chatta et al.|New England Journal of Medicine|2024Cited by 145
Wnt–β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progressionJasmin Quandt, Fotini Gounari, Stephen Arnovitz et al.|Nature Immunology|2021Cited by 89
Melanoma and microbiota: Current understanding and future directionsBertrand Routy, Laurence Zitvogel, Tanisha Jackson et al.|Cancer Cell|2023Cited by 78
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A. Yap, Lu Gan, Randy F. Sweis et al.|Nature Medicine|2026Cited by 2